We solve complex global health challenges by harnessing resources and expertise from across our company that combine research and development, access to care and advocacy to advance health around the world.
Through our activities, we have three main goals. We aim to help ensure that every child is born HIV-free, that adolescent girls and young women have the tools they need to stay HIV-free and that people living with HIV have access to the medicines they need.
We aim to help eliminate deaths from extensively drug-resistant and multi drug-resistant tuberculosis, and to simplify treatment and care. And we aim to help end preventable maternal, newborn and child deaths to ensure that every child thrives.
Innovation can help rewrite the script for girls and young women affected by HIV.
In the Sustainable Development Goals, the world has set out an ambitious and necessary vision of well-being for all people no matter where they live.
United with our partners, our ultimate goal is to help ensure that every baby is born HIV-free, adolescents and adults stay HIV-free, and people living with HIV have access to the medicines they need.
We recognize the importance and the value of effective partnerships and it is with this approach that we as a global community can end TB.
We know that healthy communities start with healthy and educated girls. Our partnerships have improved the health of mothers, newborns and adolescents, which contributes to strong communities and nations.
In 2014, the European Commission granted conditional approval to SIRTURO® (bedaquiline) in the EU, for use as part of an appropriate combination therapy for pulmonary MDR-TB in adult patients.
In 2014, Janssen and the International Partnership for Microbicides expanded their collaboration for the development and delivery of the medicine Dapivirine for the prevention of HIV.
Johnson & Johnson was ranked third in the 2014 Access to Medicine Index, which ranks companies by how they make medicines, vaccines and diagnostics accessible in low- and middle-income countries.
With the support of the European Commission, in 2015 Johnson & Johnson announced the formation of the Ebola Vaccine Development Consortia to accelerate Ebola vaccine development and patient education.
In 2015, Johnson & Johnson started an Ebola vaccine clinical trial in Sierra Leone, marking the first study of Janssen's vaccine in a country with an Ebola outbreak.
In 2016, Johnson & Johnson launched its Global Public Health Strategy and on-the-ground Africa operations in Cape Town, South Africa.
In 2016, Johnson & Johnson participated in the inaugural Financing and Innovation in Global Health conference to encourage collaboration between financial organizations, entrepreneurs and technologists to spur innovation in global health.
In 2016, a public-private partnership with Johnson & Johnson published positive phase 1 data for an Ebola vaccine regimen in JAMA.
In 2016, the anti-HIV advocacy organization m2m and Johnson & Johnson celebrated 10 years of partnership. At AIDS 2016, data released showed that mother-to-child HIV transmission was virtually eliminated among m2m’s clients for the second year in a row.
Johnson & Johnson joined 12 pharmaceutical companies in 2016 to pledge to four key commitments they will deliver by 2020 to reduce antimicrobial resistance.
The U.S. Food & Drug Administration approved Vermox™ chewable (mebendazole) in 2016 for the treatment of children and adults with roundworm and whipworm infections.
In 1900, our first Scientific Director, Fred Kilmer, created an exam to improve an understanding of public health issues, in particular contagious diseases, for a class he taught to Johnson & Johnson employees.
During the 1910s, Johnson & Johnson sponsored National Clean Up Weeks to improve public health.
During and after the 1918 Spanish Flu epidemic, Johnson & Johnson produced and distributed epidemic masks to help prevent the spread of disease.